Form D · Biotechnology

Kineta, Inc.

Seattle, WA · CIK 0001479365

Offering snapshot reported Jun 15, 2022 · SEC filing

Reported sold
$17.4M
Offering amount: $27.3M
Investors reported
19
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
May 28, 2021
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$8.7M$17.4MJun 11, 2021: $10,000,000.00Jun 11, 2021Nov 24, 2021: $16,339,605.00Nov 24, 2021Jun 15, 2022: $17,397,819.00Jun 15, 2022

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$16,339,605 → $17,397,819
  • Reported investors10 → 19

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jun 15, 2022Amendment$17,397,819$1,058,214vs Nov 24, 202119SEC filing
Mar 1, 2022Initial$2,400,000No comparison1SEC filing
Nov 24, 2021Amendment$16,339,605$6,339,605vs Jun 11, 202110SEC filing
Jul 13, 2021Initial$1,181,448No comparisonNot reportedSEC filing
Jun 11, 2021Initial$10,000,000No comparisonNot reportedSEC filing
Nov 6, 2020Amendment$2,950,100$0vs Feb 25, 20209SEC filing
Nov 6, 2020Amendment$3,331,000$0vs Oct 21, 201921SEC filing
Nov 6, 2020Amendment$5,000,000$0vs Sep 11, 20171SEC filing
Nov 6, 2020Amendment$9,000,000$0vs Sep 22, 20172SEC filing
Jun 4, 2020Initial$100,001No comparison1SEC filing
May 21, 2020Amendment$4,650,500$4,605,500vs May 9, 201943SEC filing
Feb 25, 2020Amendment$2,950,100$2,700,100vs Oct 21, 20199SEC filing
Oct 21, 2019Initial$250,000No comparison1SEC filing
Oct 21, 2019Amendment$3,331,000$3,081,000vs Jan 31, 201721SEC filing
Sep 26, 2019Amendment$2,496,546$1,281,263vs Feb 7, 201922SEC filing
May 9, 2019Initial$45,000No comparison2SEC filing
Feb 7, 2019Amendment$1,215,283$1,189,399vs Nov 16, 201715SEC filing
Nov 30, 2018Amendment$1,878,610$1,687,010vs Nov 28, 201746SEC filing
Sep 27, 2018Initial$7,060,315No comparison134SEC filing
Nov 28, 2017Initial$191,600No comparison3SEC filing
Nov 16, 2017Initial$25,884No comparison1SEC filing
Oct 23, 2017Amendment$24,369,000No comparison182SEC filing
Oct 20, 2017InitialYet to sellNo comparison0SEC filing
Sep 22, 2017Initial$9,000,000No comparison1SEC filing
Sep 13, 2017Initial$500,000No comparison1SEC filing
Sep 11, 2017Initial$5,000,000No comparison1SEC filing
Feb 28, 2017Initial$500,000No comparison1SEC filing
Feb 28, 2017Initial$47,250No comparison2SEC filing
Jan 31, 2017Initial$250,000No comparison1SEC filing
Jun 20, 2016Initial$1,752,688No comparison20SEC filing
Jul 8, 2014Initial$1,565,650No comparison6SEC filing
Jan 7, 2010Initial$942,455No comparison25SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
Yes
Business combination
No
Sales commissions
$900K (estimated)
Finders' fees
$0
Form D file number
021-402516

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Alta Companies Ltd.None

Source: Form D, filed Jun 15, 2022. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Michael Banks Executive
Raymond Bartoszek Director
William Cadwallader Executive
Campion Fellin Executive
Marion R. Foote Director
Lucien Fouke Iii Executive
Robert Hedequist Executive
Jiyoung Hwang Director
Shawn Iadonato Director, Executive
Pauline Kenny Executive
Shawn Ladonato Director, Executive
Charles Magness Director
Don Merlino Director
Steven Mitchell Director
Kenneth North Executive
Kevin Oh Director
Kyungwon Oh Director
Craig Philips Executive
Richard Samuelson Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
219 Terry Ave. N. Suite 300
Seattle, WA, 98109-5208